Results 141 to 150 of about 20,230 (187)
Some of the next articles are maybe not open access.

Familial lupus anticoagulants

British Journal of Haematology, 1987
SummaryThree families having more than one affected member with SLE or lupus‐like disease were investigated by global coagulation tests as well as methods based on dilute thromboplastin, Russell's viper venom and thermal stability/absorption, and by RIA for anticardiolipin (CL) antibodies. Of the 19 persons, 11 had SLE or lupus‐like disease.
I J, Mackie, C B, Colaco, S J, Machin
openaire   +2 more sources

Lupus Anticoagulant Testing

2013
Antiphospholipid antibodies are a heterogenous group of autoantibodies directed against glycoproteins in concert with anionic phospholipids. In clinical laboratory practice, antiphospholipid antibody evaluations usually consist of a combination of the following: anticardiolipin antibody assay, anti-beta 2 glycoprotein I assay, and at least two lupus ...
Karen, Moffat   +2 more
openaire   +2 more sources

Lupus anticoagulant and pregnancy

American Journal of Obstetrics and Gynecology, 1985
A subset of women with a high rate of fetal wastage is identifiable among those with serologic but not necessarily clinical evidence of connective tissue disease. The presence of lupus anticoagulant in the plasma of a pregnant woman serves as a marker for a high rate of fetal wastage and risk of thrombosis. Lupus anticoagulant is best identified by the
W F, Lubbe, G C, Liggins
openaire   +2 more sources

Lupus anticoagulants in children

Current Opinion in Hematology, 2003
Lupus anticoagulant and ACAs are made up of heterogeneous IgG and IgM antibodies that prolong in vitro clotting times and are associated with increased risks of venous and arterial thrombosis, recurrent fetal loss, and autoimmune thrombocytopenia and anemia.
Michael, Briones, Thomas, Abshire
openaire   +2 more sources

Lupus anticoagulant in myelofibrosis

The American Journal of the Medical Sciences, 1976
A patient with myelofibrosis who also demonstrates a lupus anticoagulant is reported. The presence of a circulating anticoagulant adds to the list of potential hemorrhagic diatheses in myelofibrosis and also demonstrates myelofibrosis to involve a system that may be separate from the myeloid elements of the bone marrow.
B, Bernhardt, M, Valletta
openaire   +2 more sources

Screening for the lupus anticoagulant

La Ricerca in Clinica e in Laboratorio, 1989
The lupus anticoagulant may be defined as an immunoglobulin (IgG, IgM or both) which interferes with one or more of the in vitro phospholipid-dependent tests of coagulation. For many years, lupus anticoagulants were regarded as a laboratory nuisance; consequently, reagents were often selected on the basis of insensitivity to lupus anticoagulants ...
openaire   +2 more sources

Lupus Anticoagulant Assays

Seminars in Thrombosis and Hemostasis, 1994
H, Messmore   +4 more
openaire   +2 more sources

[Lupus anticoagulant].

Rinsho byori. The Japanese journal of clinical pathology, 1993
Lupus anticoagulant (LAC) is an acquired inhibitor of prothrombin activator complex, which probably interferes with the phospholipid portion. Characteristically, LAC prolongs the partial prothrombin time, but only slightly prolongs the prothrombin time. It is a paradoxical fact that LAC is characterized by thrombosis.
A, Yoshida, K, Morozumi
openaire   +1 more source

"LUPUS" ANTICOAGULANT AND PROSTACYCLIN

The Lancet, 1981
L O, Carreras, J, Vermylen
openaire   +2 more sources

Home - About - Disclaimer - Privacy